Foresee Pharmaceuticals Co Ltd (6576) - Total Liabilities
Based on the latest financial reports, Foresee Pharmaceuticals Co Ltd (6576) has total liabilities worth NT$593.99 Million TWD (≈ $18.71 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Foresee Pharmaceuticals Co Ltd equity growth rate to track the company's year-over-year net asset growth rate.
Foresee Pharmaceuticals Co Ltd - Total Liabilities Trend (2017–2024)
This chart illustrates how Foresee Pharmaceuticals Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 6576 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Foresee Pharmaceuticals Co Ltd Competitors by Total Liabilities
The table below lists competitors of Foresee Pharmaceuticals Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Edom Technology Co Ltd
TW:3048
|
Taiwan | NT$22.37 Billion |
|
Community Health Systems Inc
NYSE:CYH
|
USA | $14.14 Billion |
|
PTG Energy PCL
BK:PTG
|
Thailand | ฿45.64 Billion |
|
Dagang Nexchange Bhd
KLSE:4456
|
Malaysia | RM1.75 Billion |
|
Future Generation Australia Ltd
AU:FGX
|
Australia | AU$38.17 Million |
|
GP-Act III Acquisition Corp. Class A Ordinary Share
NASDAQ:GPAT
|
USA | $15.26 Million |
|
Huang Hsiang Construction Corp
TW:2545
|
Taiwan | NT$47.78 Billion |
|
North American Construction Group Ltd
TO:NOA
|
Canada | CA$1.36 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Foresee Pharmaceuticals Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Foresee Pharmaceuticals Co Ltd (6576) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Foresee Pharmaceuticals Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Foresee Pharmaceuticals Co Ltd (2017–2024)
The table below shows the annual total liabilities of Foresee Pharmaceuticals Co Ltd from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$560.15 Million ≈ $17.65 Million |
-9.20% |
| 2023-12-31 | NT$616.93 Million ≈ $19.44 Million |
+56.81% |
| 2022-12-31 | NT$393.43 Million ≈ $12.40 Million |
+22.47% |
| 2021-12-31 | NT$321.26 Million ≈ $10.12 Million |
+18.81% |
| 2020-12-31 | NT$270.40 Million ≈ $8.52 Million |
+138.45% |
| 2019-12-31 | NT$113.40 Million ≈ $3.57 Million |
-10.00% |
| 2018-12-31 | NT$125.99 Million ≈ $3.97 Million |
+26.71% |
| 2017-12-31 | NT$99.44 Million ≈ $3.13 Million |
-- |
About Foresee Pharmaceuticals Co Ltd
Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release … Read more